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E-mail address: ecker@salk.edu (J.R. Ecker).Methylation of cytosines is a pervasive feature of eukaryotic genomes and an important epigenetic
layer that is fundamental for cellular differentiation processes and control of transcriptional poten-
tial. DNA methylation patterns can be inherited and inﬂuenced by the environment, diet and aging,
and disrupted in diseases.
Complete DNAmethylomes for several organisms are now available, helping clarify the evolutionary
story of this epigenetic mark and its distribution in key genomic elements. Nonetheless, a complete
understanding of its role, the mechanisms responsible for its establishment and maintenance, and
its cross talk with other components of cellular machinery remains elusive.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction complex interplay of DNA methylation with other epigenetic andMethylation at the carbon 5 position of cytosines (5meC) consti-
tutes an important epigenetic layer that contributes to the deﬁni-
tion of transcriptional and regulatory potential of genomic DNA
[1,2]. DNA methylation is a typical characteristic of most eukary-
otes and some of its features are conserved in many species. While
cytosine methylation is a stable modiﬁcation of the genomic DNA
that can be inherited, it also dynamically changes during the life-
span of certain cells and tissues of an organism and it is susceptible
to diet and other environmental inﬂuences. Indeed, it is essential
for the correct onset of differentiation processes and for deﬁning
tissue speciﬁc transcriptional proﬁles, and can be dysregulated in
disease states. Recently, methods have been developed for the
genome-wide detection of 5meC, and complete maps for several
organisms are available, including humans. Currently available
high-throughput data combined with results from classic genetic
experiments are beginning to clarify the roles of DNA methylation
in a variety of processes. Nonetheless, the mechanisms for the
establishment and maintenance of epigenetic patterns and thechemical Societies. Published by E
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gramming of DNA methylation is critical when considering regen-
erative medicine for the generation of induced pluripotent stem
cells (iPSCs) with full differentiation potential. However, base-res-
olution iPSCs DNA methylomes are not yet available. Several stud-
ies have shown that methylation proﬁles of iPSCs are aberrant with
respect to those of embryonic stem cells (ESC) and these differ-
ences may decrease or restrict the differentiation potential [4,5].
Additionally, aberrant methylation in iPSCs was observed to be
inherited from the progenitor cell type [6]. In general, additional
genome-wide high-resolution data from both healthy and diseased
cells will be required to shed light on the dynamic variation of
these marks, their role in healthy cells, and their relevance in
diseases.
2. Methods for determining genome-wide proﬁles of DNA
methylation
Recently, a plethora of new methods have been developed for
the determination of genome-wide DNA methylation patterns
[7]. These developments are beginning to contribute to our com-
prehension of the role of this epigenetic mark in both development
and disease states. Traditionally, DNA methylation could be deter-
mined only for speciﬁc loci through Sanger sequencing of bisulﬁte
converted and PCR ampliﬁed genomic DNA fragments. While so-
dium bisulﬁte has no effect on 5meC, it speciﬁcally converts cyto-
sine to uracil, and during PCR ampliﬁcation of bisulﬁte treated
DNA, uracil is replaced with thymine.
Several methods have been developed which enable capture of
genome-wide proﬁling of DNA methylation. These can be dividedlsevier B.V. All rights reserved.
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ments, (2) digestion with methylation-sensitive restriction en-
zymes (RE) and (3) sequencing of bisulﬁte converted DNA. Each
of these methods have been scaled for the analysis of genome-wide
proﬁles with quantiﬁcation of methylation being based on either
microarrays or high-throughput DNA sequencing.
Methylated DNA immunoprecipitation (MeDIP) is the most
common method based on enrichment, where an antibody speciﬁc
for 5meC is used to capture methylated genomic DNA fragments
[8,9]. This method can provide relatively cheap and reasonably
comprehensive genome-wide data, but the resolution is limited
and the enrichment is not linearly related to the actual methyla-
tion level [10]. Exemplifying methods based on methylation sensi-
tive RE, the HpaII tiny fragment enrichment by ligation-mediated
PCR assay (HELP) can be used to determine genome-wide patterns
based on the combined activity of HpaII and MspI restriction en-
zymes (RE) [11]. The main disadvantages of this approach are in
the resolution of the data and the bias due to the non-uniform dis-
tribution of RE cutting sites. The only methods that currently pro-
vide genome-wide base-resolution methylation information are
based on high-throughput sequencing of bisulﬁte converted DNA
[12,13]. While these methods (BS-Seq and MethylC-Seq) are still
relatively expensive for large genomes (currently $10,000 for
30 coverage of the human genome), the cost of sequencing is dra-
matically decreasing at greater than Moore’s law pace (doubling
every 18 months), meaning that soon the cost of enrichment will
be signiﬁcantly greater than the cost of sequencing.
Alternative methods to target speciﬁc regions of the genome
have also been developed. Some of these methods allow choosing
of the target regions, like padlock-probe based targeting or enrich-
ment methods coupled with promoter tiling arrays [4,9]. Another
method, reduced representation bisulﬁte sequencing (RRBS) relies
on a combination of RE fragment size selection, and bisulﬁte
sequencing, in order to fractionate the genome and enrich for frag-
ments with high CpG content regions prior to sequencing [14].
In a recent study the coverage, resolution, cost and concordance
of four sequencing-based methylation proﬁling methodologies
were evaluated [15]. The concordance between these technologies
was quite high when comparing methods based on sequencing of
bisulﬁte converted DNA (up to 82% and 99% for mC in CG and
non-CG sequence context, respectively), and when comparing
enrichment methods (99%), while regions assessed by all four
methods were 97% concordant. The authors also showed the power
of integration of two complementary methods, in that enriching
for hyper- and hypo-methylated regions, along with histone meth-
ylation, RNA, and SNP could allow for assessment of allele-speciﬁc
epigenetic states.
The choice of the best-suited method depends inevitably on re-
quired data resolution, cost, size of the genome and throughput in
the number of samples [7].3. Methylation types
In prokaryotes a methyl group can be added to both cytosines
and adenine in palindrome target sequences [16] while in eukary-
otes DNA methylation is restricted to cytosines. The most common
sequence context where this epigenetic mark is found is the CpG
(or CG) di-nucleotide [methyl-CpG (mCpG) or mCG]. This di-
nucleotide is under represented in eukaryotic genomes because of
themutagenic effect of thismodiﬁcation [17]. In fact the few regions
that are GC and CpG rich, named CpG islands (CGI), are usually de-
pleted of 5meC [17]. CGI are often within upstream gene regulatory
regions and their presence, alteredmethylation status, and the over-
all CpG content of the promoter regions are highly predictive of the
transcriptional potential of the downstream gene [18].In several eukaryotic organisms 5meC can also be found in other
sequence contexts [16]. In general, this type of modiﬁcation is
named non-CG methylation. In particular 5meC in the CHG and
CHH sequence context were found [methyl-CHG (mCHG) and
methyl-CHH (mCHH), respectively; H being A, C or T]. Recently,
pervasive non-CG methylation was found in the human genome,
even if in restricted differentiation stages [19,20] (see following
sections).
Certain genomic regions are enriched in 5meC within speciﬁc
sequence contexts. For example, mCHH are highly enriched in
A. thaliana transposons [13]. Indeed, in some organisms different
enzymes and pathways are responsible for these alternative types
of methylation, while for others this is still open to debate [21].
Recently, the presence of an additional DNA methylation mod-
iﬁcation, 5-hydroxy-methylcytosine (5hmC), was found in mouse
Purkinje neurons and the brain [22]. This base can be detected
using thin-layer chromatography, while standard RE and bisulﬁte
conversion based methods appear not to be able to reveal it [23].
Importantly, TET proteins can oxidize 5meC to 5hmC, which is
poorly recognized by DNMT1 and can be converted to cytosine,
providing a possible pathway for passive de-methylation [24].4. Establishment andmaintenance of DNAmethylation patterns
Most species where this epigenetic mark is present have two
general types of enzymes: de novo and maintenance DNA methyl-
transferases (DNMTs) [21]. The mechanism by which methylation
patterns are established, maintained and inherited is not com-
pletely clariﬁed in any species though [25]. The common paradigm
is that de novo DNMTs (DNMT3A and DNMT3B in human) estab-
lish methylation patterns early in embryonic development [26].
These enzymes have the same activity on both hemi- and un-
methylated DNA and are down-regulated but still expressed after
cell differentiation [27]. Maintenance enzymes (DNMT1 in human)
then copy the newly established DNA methylation patterns
through each cellular division [28]. DNMT1 has a preference for
hemi-methylated DNA while showing some de novo activity
[29,30]. The picture seems to be more complex though, since ge-
netic experiments with gene knock-outs for these enzymes suggest
that the concerted activity of de novo and maintenance enzymes is
required for the complete and correct establishment of methyla-
tion proﬁles [25]. Nevertheless, their expression varies greatly dur-
ing the differentiation processes, suggesting that the requirement
for their activity is not constant. Moreover, these enzymes appear
not to be freely available in the cells but rather associated with
chromatin complexes or at the DNA replication fork [27]. Finally,
these enzymes require accessory proteins and show a complex
interplay with nucleosome positioning and particular histone
marks [31]. These ﬁndings help to explain why not all cytosines
are methylated. A revised model points to the possibility that the
overall methylation level of a region might be copied rather than
the exact methylation status of each individual cytosine [27].
In general, the complex cross-talk of these enzymes with other
components of the transcriptional machinery has to be considered.
In fact, as discussed in the following sections, despite DNA methyl-
ation being usually considered a repressive mark, its role can vary
greatly in different genomic contexts, in associations with other
regulatory mechanisms.5. Methylomes and evolution
The role of DNA methylation in different genomic contexts can
be remarkably different, and alternative mechanisms are available
for establishing 5meC patterns in different genomic regions. The
density of possible methylation sites, as well as the distribution
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methylation levels in promoters, gene bodies, regulatory features,
and transposable and repetitive elements appears to be critical.
Recently, base-resolution sequencing of several eukaryotic
methylomes has provided initial insights into the evolutionary his-
tory of DNA methylation and its distribution in these key genomic
regions. Currently, the complete methylomes for 23 organisms are
available (10 animals, 8 plants and 5 fungi; Fig. 1) [13,19,32,33]. In
general the DNA methylation landscape can be either continuous
along the genome, or constituted by a series of heavily methylated
DNA domains interspersed with domains that are methylation free.
When considering the data available for a limited set of loci in an
even wider set of organisms, the current perspective is that the
evolutionary history of DNA methylation in gene bodies and trans-
posons may be independent. These genomic regions are present in
both plants and vertebrates; however, transposon methylation is
only conserved in fungi while gene body methylation only occurs
in invertebrates [16]. Gene body methylation seems to be a prop-
erty inherited from ancient genomes, while transposon methyla-
tion appears to be related to the degree of sexual outcrossing
[27]. In general, for those organisms where the methylation of cer-Fig. 1. Methylation levels in 23 eukaryotic organisms. The organisms are organized ac
Taxonomy (http://www.ncbi.nlm.nih.gov/guide/taxonomy/) and displayed using TreeV
size is indicated together with the percentage of methylated sites within three sequenctain genomic elements was present, their methylation pattern is
quite conserved. However, the presence of non-CG methylation is
less common, but when present, it is always at a lower level than
mCG [13,19,32,33].6. Human methylomes
Base-resolution global maps of DNA methylation in humans re-
mained elusive for a long time because of the difﬁculties of per-
forming comprehensive analysis on a multiple-gigabase genome.
Recent improvements in the throughput of sequencing technolo-
gies, simultaneous reduction of the cost, and coupling of bisulﬁte
conversion with cutting edge sequencing methods, has now en-
abled acquisition of the complete human methylomes for several
cell types: human embryonic stem cells (hESC), fetal and neonatal
ﬁbroblasts, and ﬁbroblastic differentiated derivative of hESC
[19,20]. The choice of these particular cell types is related to the
relevance of DNA methylation in the onset and regulation of cellu-
lar differentiation processes. These maps demonstrated for the ﬁrst
time the feasibility of applying such genome-wide methods oncording to their evolutionary distance. Tree topology is determined from the NCBI
iew X (http://darwin.zoology.gla.ac.uk/~rpage/treeviewx/index.html). The genome
e contexts: CpG, CHG and CHH (H being A, C or T).
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which other maps of healthy and diseased cells can be compared.
6.1. Non-CG methylation
A striking ﬁnding from the ﬁrst human methylomes is the rela-
tive abundance of non-CGmethylation in hESC [19,20]. Indeed, one
quarter of the 5meC was present in the CHG or CHH sequence con-
text, with some preference for CA di-nucleotides in both sequence
contexts. Moreover, non-CG methylation was lost during the dif-
ferentiation process but can be re-established at the same loci
upon generation of iPSCs [19]. While the re-appearance of non-
CG methylation in iPSCs was shown for several loci, more compre-
hensive experiments will be necessary to fully evaluate how the
DNA methylome is restored in these cells compared to ESCs.
Non-CG methylation was distributed non-randomly in the genome
and was particularly enriched in the gene bodies, with increasing
levels corresponding to more highly transcribed genes [19]. Non-
CG methylation was also particularly enriched in genes related
with processing of mRNA and in genes having higher pre-mRNA
levels [19]. These ﬁndings point to the potential involvement of
DNA methylation with the splicing machinery [19,20]. This
hypothesis is also supported by the patterns of CG methylation
at the exon–intron boundaries [20]. Enzymes responsible for the
deposition of mCG were shown to have a preference for targeting
CG di-nucleotides with a relative spacing of 8 bp [34]. Interestingly,
the same result was observed for 5meC in CHG and CHH sequence
contexts [19]. These ﬁndings suggest that the same enzymes may
be responsible for non-CG methylation, even if patterns for 5meC
at relative distances multiple of 8 bp are not found as clearly as
for mCG. Interestingly, methylation at non-CG was much lower le-
vel than mCG as only 25% of the sequencing reads for a given non-
CG residue were methylated, compared to 80–90% for mCG [19].
Finally, mCHH was slightly more enriched on the antisense strand
in gene bodies, and the potentially symmetric mCHG was 98%
hemi-methylated [19]. For all of these reasons, it is necessary to ac-
quire deep sequence coverage for those samples where non-CG
methylation is expected. Finally, further research will be necessary
to clarify the role of non-CG methylation and its relevance for
pluripotency.
6.2. Methylation of regulatory elements
Biophysical studies of DNA methylation reveal that this base
modiﬁcation plays an important role in repressing accessibility of
the transcriptional machinery to the DNA [35]. Indeed, some tran-
scription factors (TF) such as Sp1 are known to be methylation sen-
sitive, even if this seems to be dependent on the considered
condition or tissue [36,37]. Moreover, not all TFs have methylation
sites in their binding sites [transcription factor binding site (TFBS)]
or methylation does not affect their binding.
Recently, binding of TFs and other proteins important for gen-
eral control of transcription (TAF1 and P300) or for the stem cell
biology (SOX2, OCT4, NANOG and KLF4) was proﬁled by chromatin
immunoprecipitation (ChIP)-seq in both hESC and fetal ﬁbroblasts
[19]. The regions immediately surrounding these TFBS showed
depletion of non-CG 5mC in human ESCs, while mCG were much
less depleted for many factors [19].
Enhancer regions, as deﬁned by H3K4me1 and H3K27ac ChIP-
seq sites, were also proﬁled and these elements also showed deple-
tion of non-CG 5mC in human ESCs. Interestingly, the enhancers
present in ﬁbroblasts showed mCpG depletion, while enhancers
shared by both cell types showed depletion of 5meC in the CpG
and non-CG context in differentiated and un-differentiated cells,
respectively. These ﬁndings would suggest that cells in differentstates of differentiation use different DNA methylation mecha-
nisms to mark these important regulatory features [19].
6.3. Differential methylation
While non-CG methylation was absent in differentiated cells,
widespread differences were found in the distribution and levels
of CG methylation. Hundreds of differentially methylated regions
(DMRs) hyper-methylated in ﬁbroblasts have been identiﬁed,
many associated with genes important for stem cells functions
[19]. On the other hand, large hypo-methylated regions have also
been identiﬁed when comparing differentiated cells to human
ESCs. These have been termed partially methylated domains
(PMDs). PMDs might also be expected on the chromosome X, given
that the cells examined were derived from a female and that the
dosage compensation occurs on sex chromosome. In fact PMDs
cover 80% of chromosome X. Nonetheless, surprisingly almost
40% of autosomes were found in the PMD state. Genes in these do-
mains were down-regulated compared to human ESCs, and PMDs
were also enriched in histone repressive marks [19]. Interestingly,
large blocks of H3K9me2 were present in differentiated cells but
not in embryonic cells in the mouse. These same regions were
found to overlap human PMDs and shown too be lost in certain
cancer cells [38,39].
CG DNA methylation is usually considered a repressive mark
[16]. Indeed, methylation in the context of promoters is inversely
related with the transcriptional level of the downstream gene.
However, CG methylation in gene bodies is positively correlated
with the gene transcriptional level, indicating that the meaning
of this epigenetic mark is rather complex and context dependent
[40]. Genome-wide studies showed that gene-body non-CG meth-
ylation is also clearly positively correlated with gene expression
[19]. Rather, gene bodies in human ESCs are always highly methyl-
ated, even in poorly expressed genes [19]. All of these ﬁndings sug-
gest that the positive correlation between gene-body CG
methylation and transcriptional expression could be re-interpreted
as loss of DNA methylation upon differentiation and the formation
of repressed chromatin blocks [19], rather than expecting a posi-
tive effect of gene-body methylation on gene expression. In agree-
ment, there is evidence in A. thaliana for association between gene
body methylation and transcriptional elongation, suggesting a sce-
nario where transcription contributes to maintaining or enhancing
DNA methylation levels [41].
7. Data analysis
There are speciﬁc pitfalls related to the analysis of DNA methyl-
ation data. Some of these issues are speciﬁc to the methodology
chosen for detecting 5meC. For example, a problem for enrichment
methods is that the enrichment signal is not linearly related to the
actual methylation level (Fig. 2A). Fortunately, several methods
were developed to correct for this bias [10,42,43]. When analyzing
base-resolution data the challenges are in dealing with non-
uniform coverage within a sample and comparing samples with
different overall sequencing depth (Fig. 2B). This is particularly
critical for the detection of non-CG methylation. In fact, as dis-
cussed in a previous section, the level of methylation for 5mC in
this sequence context is rather low, and only 25% of the sequencing
reads for a given non-CG residue are methylated in average. Rather,
alignment of bisulﬁte-converted reads and bisulﬁte conversion
errors do not represent a serious issue, since a high proportion of
reads can be mapped, covering most of the genome.
Once the ﬁnal set of 5meC calls, or an estimate derived from the
enrichment level, is available, one has to consider both the abso-
lute and relative methylation level. The absolute level represents
Fig. 2. Pitfalls in the analysis of DNA methylomes. (A) MeDIP-chip enrichment is not linearly related to the DNA methylation level (graph created using MEDME [10]). (B) The
mC calls determined for two samples with different sequencing depth; the height of the bars corresponds to the methylation level (the proportion of methylated over total
reads for a given cytosine); a differentially methylated region can be improperly identiﬁed if the depth is not considered; in addition higher methylation levels could be
computed in the sample with lower coverage. (C) Two promoters with the same number of mC but different density of available methylation sites (LCP and HCP: low and high
CpG content promoter, respectively); the increase of mC from 2 to 10 in the two promoters can have remarkably different effect on the transcription of the downstream gene
(TSS: transcriptional start site; CGI: CpG island). (D) Signal and signal-to-noise for enrichment methods (MeDIP-seq) and for bisulﬁte sequencing methods (MethylC-Seq); RE
is a repetitive region that cannot be covered.
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considered with respect to the total number of available methyla-
tion sites, and in general the CG content of the loci under consider-
ation. As an example, a promoter containing a hypo-methylated
CGI can have the same 5meC density as a fully methylated low
CpG content promoter, in absolute terms, but their functional
consequences are remarkably different (Fig. 2C). Indeed hypo-
methylation at CGI is likely to be associated with transcriptional
expression of the downstream gene. In general, it was shown that
transcription of genes downstream of low CG content promoters
does not correlate with their upstream-region DNAmethylation le-
vel. However, the methylation status of high and especially inter-
mediate CpG content promoters is critical for transcriptional
repression [18].
A substantial difference between enrichment and bisulﬁte-
sequencing based methods is that for the former the count of reads
for given loci determines the methylation level, while for the latter
the read depth is related to the library preparation, sequencing and
mapping process. Also, the ability to call a 5meC is directly related
to the sequencing depth in bisulﬁte sequencing-based experiments
(Fig. 2B). Related with this, the methylation level, the proportion of
reads with 5meC over the set of reads covering a speciﬁc base, is a
measure whose variability decreases with increasing depth. Final-ly, since the methylation level is a ﬁnite scale b-distributed mea-
sure, the variance of measurements with a mean near the mid-
range can be much larger than the variance of measurements with
a mean close to the limits (0 and 1; Fig. 2D). These are important
pitfalls to keep in mind when determining differential methylation
levels.
In general, few tools are currently available for the analysis of
epigenomics data, in particular high-throughput DNA methylation
data [7]. Pipelines for both low- and high-level analyses must be
developed. Low-level analysis can be deﬁned as read mapping
algorithms and 5meC calling, taking into account bisulﬁte conver-
sion level, sequencing errors and multiple testing issues. Higher-
level analysis involves the determination of absolute and relative
methylation levels across genomic regions based on genome
annotation, clustering, visualization and integration with other
heterogeneous data types. Particularly important is the determi-
nation of DMR, since DNA methylomes vary between different
cell types, as a function of differentiation stage, age, and as a re-
sult of disease states. Methods for the identiﬁcation of DMR
must also take into account that genomic regions of very different
scale might exist, spanning from megabase size PMDs to small
DMRs that constitute only few differentially methylated cytosine
bases.
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Technologies for high-throughput detection of the sites of DNA
methylation in genomes are being constantly improved and with
equally signiﬁcant reductions in cost. Three important limitations
might be overcome in the near future. Single cell sequencing anal-
ysis would eliminate many problems of interpreting DNA methyl-
omes, which currently are the produce of a mixed population of
cells/chromosomes, each with heterogeneous methylation status
[44,45]. Similarly, use of ‘‘ampliﬁcation-free’’ methods would
greatly reduce the problem of the uneven distribution of bisulﬁte
converted reads [44,45]. Finally, direct detection of 5meC, without
use of bisulﬁte conversion, would eliminate the issue of the degra-
dation and loss of material following the chemical conversion [44–
47] as well as increase the ability to map the sequencing reads onto
the genome.
Several aspects regarding the prevalence and role(s) of DNA
methylation must be clariﬁed. A comprehensive list of DNA-
binding proteins affected or insensitive to cytosine methylation
should be developed. This is particularly critical for TFs, given
that they bind upstream gene regulatory regions, where DNA
methylation has always been considered a critical factor. Also,
the relationship between the methylation of speciﬁc regions and
the transcriptional potential of nearby genes is still unclear. DNA
methylation is only one epigenetic control point. Future studies
must attempt to integrate this key mark with all other epigenetic
and regulatory mechanisms. For example, there is strong evidence
on the relevance of promoter DNA methylation and transcriptional
repression of the downstream gene. Induced de-methylation can
restore the expression of silenced genes, as well as re-establish-
ment of high methylation levels can suppress them [48]. However,
in other cases, variation in the level of DNA methylation may sim-
ply be a consequence of closed chromatin structure, as it has been
hypothesized for PMDs, where embryonic methylation levels
might be lost after differentiation, resulting in accumulation of
repressive chromatin marks [19].
Few examples of allelic methylation are available, but this
important phenomenon requires more comprehensive analysis
[49]. This will require the availability of matched genomes/methyl-
omes, and possibly the use of methods that are not dependent on
bisulﬁte conversion, as this complicates the evaluation of the dif-
ferential methylation for C–T SNPs.
Finally, a critical area is the application of base-resolution
methylome analysis for clinical studies where DNA methylomes
of diseased cells can be generated and compared to healthy cells,
possibly using matched samples. These studies will be also neces-
sary to better understand the effect of drugs that target the epige-
nome such as the demethylating agent Decitabine. These drugs are
used to de-methylated tumor suppressor genes that have been si-
lenced by DNA methylation [48] but their genome-wide effect is
poorly understood.
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